This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

30 Aug 2011

Abbott & Eisai to Launch Pancreatic Digestive Enzyme Replacement Drug in Japan

A pancreatic digestive enzyme replacement therapy will be launched in Japan Tuesday for the treatment of pancreatic exocrine insufficiency.

Abbott Japan Co., Ltd. and Eisai Co., Ltd. have announced that they will launch the pancreatic digestive enzyme replacement drug Lipacreon? Capsules 150 mg and Lipacreon? Granules 300mg Sachets (pancrelipase) on August 30 in Japan.


Abbott Japan received approval to manufacture and market Lipacreon? in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency (PEI) on April 22 of this year, with the drug being registered on the National Health Insurance Drug Price List on July 19. Eisai will market the Lipacreon? and ensure the provision of information on its proper use.


Lipacreon? is the first pancreatic digestive enzyme replacement therapy to be approved in Japan for the treatment of PEI due to chronic pancreatitis, pan

Related News